Headline
The latest stories from AHA Today.
The Food and Drug Administration released briefing documents for the convening of the agency’s Vaccines and Related Biological Products Advisory Committee, which will consider COVID-19 vaccine booster shot applications from Moderna and Johnson & Johnson.
The Centers for Disease Control and Prevention has released an initial document intended to assist jurisdictions across the country in planning for the distribution and administration of COVID-19 vaccines to the pediatric population.
The Health Resources and Services Administration Oct. 13 will host the third in a series of webinar sessions on how to apply for a portion of $25.5 billion in COVID-19 relief funds
The American Medical Association Oct. 6 announced Current Procedural Terminology code set updates to now include vaccine and administration codes for pediatric doses of the Pfizer COVID-19 vaccine.
The AHA restated its strong support for the Centers for Medicare & Medicaid Services’ withdrawal of its Most Favored Nation Model proposed rule.
Merck announced its submission for a Food and Drug Administration emergency use authorization of its investigational oral antiviral COVID-19 medicine.
Employment at hospitals and health systems fell by more than 8,000 jobs in September, as U.S. jobs overall increased by 194,000, according to preliminary data released by the Bureau of Labor Statistics. Health care jobs overall fell by 17,500 and remain at just under 16 million (seasonally adjusted…
The Department of Health and Human Services released a Spanish version of its QuestionBuilder app, a mobile app developed by the Agency for Healthcare Research and Quality to help patients prepare for in-person and telehealth appointments.
The Centers for Medicare & Medicaid Services released its star ratings for 2022 Medicare Advantage and prescription drug plans, which are available through the Medicare plan finder tool and CMS website.
The Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response issued details on several key changes related to the REGEN-COV COVID-19 monoclonal antibody therapy.